{"entity":{"id":"adra1d","kind":"target","name":"ADRA1D","aka":["adrenoceptor alpha 1D","Alpha-1D adrenergic receptor","ADRA1R","ADRA1A","ADRA1"],"tldr":"ADRA1D (Alpha-1D adrenergic receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.","summary":"Alpha-1 adrenergic receptors are G protein-coupled receptors for catecholamines that signal through the G(q) family of G proteins, including G(q) and G(11). Upon activation, they stimulate the phosphatidylinositol-calcium second messenger pathway, leading to calcium release from intracellular stores and activation of protein kinase C. ADRA1D binds the catecholamine ligands norepinephrine and epinephrine.\n\nOpen Targets scores its association with cancer at 0.54 (direct and indirect evidence; datatypes literature 0.29, animal model 0.26, genetic association 0.00, clinical 0.86).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:280","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:280"},{"label":"UniProt P25100","url":"https://www.uniprot.org/uniprotkb/P25100/entry"},{"label":"NCBI Gene 146","url":"https://www.ncbi.nlm.nih.gov/gene/146"},{"label":"Ensembl ENSG00000171873","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171873"}],"tags":["cancer-genes-wave"],"related":["open-targets"],"cancers":["neuroendocrine"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.86. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"ADRA1D","role":["drug-target"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:280","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:280","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P25100","url":"https://www.uniprot.org/uniprotkb/P25100/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000171873","url":"https://platform.opentargets.org/target/ENSG00000171873/associations","note":"association with cancer (MONDO_0004992) 0.54; per-cancer scores at or above 0.5: neuroendocrine neoplasm 0.51 (GraphQL API, CC0)"}],"distribution":"one-type","specificityNote":"Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA ADRA1D: RNA tissue enhanced (blood vessel 7 nTPM, brain 6 nTPM, cervix 6 nTPM); no normal tissue stained high. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Neuroendocrine tumours); Open Targets associates it with 2 specific cancer types at or above 0.5 (benign prostatic hyperplasia, adrenal gland pheochromocytoma); the corpus evidence decides and the Open Targets list is quoted for comparison. (No rule of scripts/fetch-target-specificity.ts fired.)","specificitySources":[{"label":"Human Protein Atlas ADRA1D tissue","url":"https://www.proteinatlas.org/ENSG00000171873-ADRA1D/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000171873 associations","url":"https://platform.opentargets.org/target/ENSG00000171873/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:280","ensembl":"ENSG00000171873","uniprot":"P25100","entrez":"146","firstDescribed":1991,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Bruno J.F. et al, Biochem. Biophys. Res. Commun, 1991, \"Molecular cloning and sequencing of a cDNA encoding a human alpha 1A adrenergic receptor\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/1656955/","biology":"Alpha-1 adrenergic receptors are G protein-coupled receptors for catecholamines that signal through the G(q) family of G proteins, including G(q) and G(11). Upon activation, they stimulate the phosphatidylinositol-calcium second messenger pathway, leading to calcium release from intracellular stores and activation of protein kinase C. ADRA1D binds the catecholamine ligands norepinephrine and epinephrine. Location: Cell membrane (UniProt). Locus 20p13 (HGNC).","whereFound":["Neuroendocrine tumours: Open Targets association 0.51 with neuroendocrine neoplasm (MONDO_0019496)"],"targetClass":"other","prevalence":[]},"route":"/targets/adra1d/","neighbours":{"collection":[{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"}]}}